



(Please scan the QR Code to view the RHP)

This is an abridged prospectus containing salient features of the Red Herring Prospectus of Chandan Healthcare Limited dated February 04, 2025 filed with the Registrar of Companies (the “RHP” or “Red Herring Prospectus”). You are encouraged to read greater details available in the RHP, which is available at <https://www.sebi.gov.in/sebiweb/home/HomeAction.do?doListin g=yes&sid=3&ssid=15&smid=11>. Unless otherwise specified all capitalised terms used herein and not specifically defined bear the same meaning as ascribed to them in the RHP. This abridged prospectus is not for distribution outside of India.

THIS ABRIDGED PROSPECTUS CONSISTS OF BID CUM APPLICATION FORM ALONG WITH INSTRUCTIONS AND EIGHT PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.

Please ensure that you have read the RHP, this abridged prospectus (“Abridged Prospectus”) and the General Information Document for investing in public Issues (“GID”) undertaken through the Book Building Process before applying in the Offer (as defined below). The investors are advised to retain a copy of the RHP/ Abridged Prospectus for their future reference. You may obtain a physical copy of the Bid cum Application Form and the RHP from the Stock Exchange (defined below), Syndicate Member (defined below), Registrar to the Offer, Registrar and Share Transfer Agents (“RTAs”), Collecting Depository Participants (“CDPs”), Registered Brokers, Bankers to the Issue, Investors’ Associations or Self Certified Syndicate Banks (“SCSBs”). You may also download the RHP from the website of Securities and Exchange Board of India (“SEBI”) at www.sebi.gov.in, at the website of National Stock Exchange of India Limited (“NSE”) at www.nseindia.com and the websites of our Company at www.chandandidiagnostic.com and Book Running Lead Manager at www.unistonecapital.com



CHANDAN HEALTHCARE LIMITED

Corporate Identity Number: U85110UP2003PLC193493; Date of Incorporation: September 03, 2003

Registered Office and Corporate Office	Contact Person	Email and Telephone	Website
Registered Office: Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow- 226021, Uttar Pradesh, India.	Rajeev Nain Company Secretary and Compliance Officer	Email: secretarial@chandan.co.in Telephone: +91 8429024430	www.chandandidiagnostic.com

PROMOTERS OF OUR COMPANY ARE AMARANITA HOLDINGS (INDIA) PRIVATE LIMITED, AMAR SINGH, ASMITA SINGH, ALOK SINGH, SHALEEN SOLANKI, VIJAY SINGH AND VINAY LAMBA

Details of Public Offer

Type of Offer	Fresh Issue Size	Offer for Sale size	Total Offer Size	Offer under Regulation 229(2) of the SEBI ICDR Regulations
Fresh Issue and Offer for Sale	Upto 44,52,064 Equity Shares aggregating up to ₹ [•] lakhs	Upto 22,99,936 Equity Shares aggregating up to ₹ [•] lakhs	Upto 67,52,000 Equity Shares aggregating up to ₹ [•] lakhs	The Offer is being made pursuant to Regulation 229(2) of the SEBI (ICDR) Regulations. For details in relation to share reservation among QIBs, NIIs, RIBs, see “Offer Structure” on page 380 of the RHP

The Equity Shares are proposed to be listed on Emerge Platform of NSE Limited (“NSE Emerge”) (Designated Stock Exchange).

PRICE, MINIMUM BID LOT & INDICATIVE TIMELINES**

Price Band*	₹ 151/- to ₹ 159/- per Equity Share of face value of ₹ 10/- each.
Minimum Bid Lot Size	800 Equity Shares
Bid/Offer Opens On	Monday, February 10, 2025
Bid/Offer Closes On^	Wednesday, February 12, 2025
Finalisation of Basis of Allotment with the Designated Stock Exchange	On or before Thursday, February 13, 2025
Initiation of refunds (if any, for Anchor Investors)/unblocking of funds from ASBA Account#	On or before Friday, February 14, 2025
Credit of Equity Shares to demat accounts of Allottees	On or before Friday, February 14, 2025
Commencement of trading of the Equity Shares on the Stock Exchange	On or before Monday, February 17, 2025

* For details of the Price Band and basis for Offer price, please refer to the price band advertisement and the section titled “Basis for Offer Price” on page 146 of the RHP.

**The Offer shall remain open for three days i.e. Monday, February 10, 2025, to Wednesday, February 12, 2025.

^UPI mandate end time and date shall be at 5:00 PM on Bid/Offer Closing Date

In case of any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding 4 Working Days from the Bid/ Offer Closing Date, the Bidder shall be compensated for causing such delay in unblocking in accordance with applicable law. The BRLM shall, in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in unblocking. Further, investors shall be entitled to compensation in the manner specified in the SEBI Circular no. SEBI/HO/CFD/ DIL2/P/CIR/2022/75 dated May 30, 2022 and SEBI Master Circular no. SEBI/HO/MIRSD/POD-1/P/CIR/2023/70 dated May 17, 2023 (to the extent applicable) in case of delays in resolving investor grievances in relation to blocking/unblocking of fund and the provisions shall also be deemed to be incorporated in the deemed agreement of the Company with the SCSBs to the extent applicable. The BRLM shall, in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in unblocking. For the avoidance of doubt, the provisions of the SEBI Circular no. SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022 and SEBI Master Circular no. SEBI/HO/MIRSD/POD-1/P/CIR/2023/70 dated May 17, 2023 (to the extent applicable) shall be deemed to be incorporated in the agreements to be entered into by and between the Company and the relevant intermediaries, to the extent applicable.

For more details, please see “Terms of the Offer” on page 370 of the RHP.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in ‘offshore transactions’ as defined in, and in reliance on, Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS**THE WEIGHTED AVERAGE COST OF ACQUISITION OF ALL EQUITY SHARES TRANSACTED IN THE ONE YEAR, 18 MONTHS AND THREE YEARS PRECEDING THE DATE OF THE RED HERRING PROSPECTUS**

Period	Weighted average cost of acquisition per Equity Share (in ₹)	Cap Price is 'x' times the weighted average cost of acquisition*	Range of acquisition price per Equity Share: lowest price – highest price (in ₹)
Last 1 year	10.28	15.47	₹ 0 - ₹ 16
Last 18 Months	10.28	15.47	₹ 0 - ₹ 16
Last 3 years	6.72	23.66	₹ 0 - ₹ 16

*As certified by our Statutory and Peer Review Auditor, by way of their certificate dated February 04, 2025.

RISKS IN RELATION TO THE FIRST OFFER

This being the first public offer of our Company, there has been no formal market for the Equity Shares of our Company. The face value of our Equity Shares is ₹ 10 each and the Floor Price and Cap Price are 15.10 times and 15.90 times of the face value of the Equity Shares, respectively. The Floor Price, Cap Price and the Offer Price (as determined by our Company in consultation with the BRLM, in accordance with SEBI ICDR Regulations, and as stated in “Basis for the Offer Price” beginning on page 146 of RHP should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active and/or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISK

Investments in Equity and Equity related securities involve a degree of risk and investors should not invest any funds in this offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the offer including the risks involved. The Equity Shares offered in the Offer have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the Red Herring Prospectus. Specific attention of the investors is invited to the section “Risk Factors” beginning on page 42 of the Red Herring Prospectus

PROCEDURE

You may obtain a physical copy of the Bid-cum-Application Form and the RHP from the Stock Exchange, Syndicate Member, Registrar to the Offer, Registrar and Share Transfer Agents (“RTA”), Collecting Depository Participants (“CDPs”), Registered Brokers, Banker to the Offer, Investors’ Associations or Self Certified Syndicate Banks (“SCSBs”).

If you wish to know about processes and procedures applicable to the Offer, you may request for a copy of the RHP and/or the General Information Document (GID) from the BRLM or download it from the websites of NSE www.nseindia.com and the website of the BRLM at www.unistonecapital.com.

PRICE INFORMATION OF THE BOOK RUNNING LEAD MANAGER

Sr. No.	Issue Name	Issue Size (in Lakhs)	Issue price	Listing date	Opening price on listing date	+/- % change in closing price, [+/- % change in closing benchmark]- 30 th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 90 th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 180 th calendar days from listing
MAIN BOARD								
1.	Exicom Tele-Systems Limited	42,899.90	142	March 05, 2024	265.00	46.41% [0.71%]	113.49% [4.06%]	171.51% [12.88%]
2.	Platinum Industries Limited	23,531.69	171	March 05, 2024	225.00	19.36% [0.71%]	15.32% [4.06%]	143.19% [12.88%]
3.	Saraswati Saree Depot Limited	16,001.28	160	August 20, 2024	194.00	6.98% [2.90%]	-20.96% [-5.04%]	-
4.	Shree Tirupati Balajee Agro Trading Company Limited	16,965.20	83	September 12, 2024	90.00	-7.37% [-1.67%]	-6.18% [-2.94%]	-
5.	Arkade Developers Limited	41,000.00	128	September 24, 2024	175.00	7.30% [-6.17%]	27.28% [-8.43%]	-
6.	Diffusion Engineers Limited	15,796.40	168	October 04, 2024	193.50	119.17% [-2.84%]	102.32% [-3.30%]	-
SME PLATFORM								
6.	Manglam Infra & Engineering Limited	2,761.92	56	July 31, 2024	106.40	19.73% [1.14%]	-10.89% [-1.94%]	-32.14% [-8.50%]
7.	Deccan Transcon Leasing Limited	6,505.92	108	September 24, 2024	116.00	-42.59% [-6.17%]	-46.20% [-8.43]	-
8.	OBSC Perfection Limited	6,602.40	100	October 29, 2024	110.00	75.30% [-2.26%]	101.65% [-6.69%]	-
9.	Usha Financial Services Limited	9,844.80	168	October 31, 2024	164.00	-30.33% [-0.31%]	-40.57% [-4.31%]	-

Source: www.nseindia.com

(1) NSE Emerge as Designated Stock Exchange.

Notes:

- Offer Size derived from Prospectus/final post issue reports, as available.
- The CNX NIFTY is considered as the Benchmark Index as per the Designated Stock Exchange disclosed by the respective Issuer at the time of the issue, as applicable.
- Price on NSE is considered for all of the above calculations as per the Designated Stock Exchange disclosed by the respective Issuer at the time of the issue, as applicable.
- In case 30th/90th/180th day is not a trading day, closing price of the previous trading day has been considered.
- Since 30 calendar days, 90 calendar days and 180 calendar days, as applicable, from listing date has not elapsed for few of the above issues, data for same is not available.

For further details, please refer ‘Other Regulatory and Statutory Disclosures - Price information and track record of past issues handled by the Book Running Lead Manager’ on page 247 of the RHP.

Book Running Lead Manager	Unistone Capital Private Limited Tel: 022-4604 6494 E-mail: mb@unistonecapital.com Investor Grievance E-mail Id: compliance@unistonecapital.com
----------------------------------	--

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Name of Syndicate Member	R.K. Stockholding Private Limited
Name of Market Maker	R.K. Stockholding Private Limited
Name of Registrar to the Offer	KFin Technologies Limited Tel: +91 40 6716 2222 E-mail: chl.ipo@kfintech.com Investor grievance E-mail: einward.ris@kfintech.com
Name of Statutory and Peer Review Auditor	M/s. MSNT & Associates LLP, Chartered Accountant
Name of Credit Rating Agency and the rating or grading obtained, if any	Not Applicable
Name of Debenture Trustee	Not Applicable
Self-Certified Syndicate Banks	The list of Self Certified Syndicate Banks that have been notified by SEBI to act as Investors Bank or Issuer Bank for UPI mechanism are provide on the website of SEBI on https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=41 , For details on Designated Branches of SCSBs collecting the Bid Cum Application Forms, please refer to the above-mentioned SEBI link.
Details regarding website address(es)/ link(s) from which the investor can obtain a list of RTAs, CDPs and stock brokers who can accept applications from investors, as applicable:	The list of the RTAs eligible to accept ASBA Forms from investors (other than RIBs) at the Designated RTA Locations, including details such as address, telephone number and e-mail address, is provided on the websites of SEBI (www.sebi.gov.in) at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes ,respectively, as updated from time to time. For further details, see “Offer Procedure” on page 386 of the RHP. The list of the CDPs eligible to accept ASBA Forms at the Designated CDP Locations, including details such as name and contact details, is provided on the website of SEBI (www.sebi.gov.in) at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes , respectively, as updated from time to time.

PROMOTERS OF OUR COMPANY

Sr. No.	Name	Individual / Corporate	Experience & Educational Qualification
1.	Amar Singh	Individual	He holds a degree of Bachelor of Medicine and Bachelor of Surgery. He has over two decades of experience in the healthcare industry.
2.	Asmita Singh	Individual	She holds a Bachelor of Business Administration and Master of Business. She has over two decades of experience in the field of marketing.
3.	Alok Singh	Individual	He holds Bachelor of Technology (Information Technology) degree from Amity University and Master of Business Administration from India Institute of Technology, Madras. He was previously associated with Wipro Technologies as Project Engineer from 2016 to 2018. He is associated with Chandan Hospitals Limited since 2018.
4.	Shaleen Solanki	Individual	He holds Bachelor of Science degree from Kumaun University and Post Graduate Diploma in Business Management from Institute of Productivity & Management.
5.	Vijay Singh	Individual	He has cleared Bachelor of Arts and holds a Post Graduate Diploma in Computer Engineering. He has more than twenty years of experience under information technology.
6.	Vinay Lamba	Individual	He has completed his training from the Marine Engineering and Research Institute, Calcutta and has a certificate of competency as Marine Engineer Officer Class I of a Motorship. He has over one decade of experience in the field of technical operations. He was previously associated with Indra Diagnostic Centre and Blood Bank Limited as Operations head from 1999 to 2003.
7.	Amaranita Holdings (India) Private Limited (AHIPL)	Corporate	Amaranita Holdings (India) Private Limited (AHIPL) was incorporated on May 14, 2008 as a private limited company under the Companies Act, 1956. The registered office of AHIPL is situated at 40, Chandan Vihar Faridi Nagar, Lucknow- 226015, Uttar Pradesh, India. The corporate identity number is U65993UP2008PTC035234. AHIPL is engaged in the business of investment and underwrite, sub underwrite, to invest in and acquire and hold, sell, buy, or otherwise deals in shares, debenture, stock, bonds, unity, property, obligations & securities issued, other forms of investment and provide consultancy services in shares, securities and related activities. Company will not carryout in business of N.B.F.C.

For details in respect of our Promoters, please see the section titled “Our Promoters and Promoter Group” beginning on page 217 of the RHP.

OUR BUSINESS OVERVIEW AND STRATEGY

Company Overview: Our Company was incorporated as a public limited Company under the name “Chandan Healthcare Limited”, under the provisions of the Companies Act, 1956 and Certificate of Incorporation was issued by the Registrar of Companies, U.P. & Uttaranchal, Kanpur on September 03, 2003. The corporate Identification Number is U85110UP2003PLC193493. We run a diagnostic network in North India with pathology and radiology testing services. As of December 31, 2024, we have one flagship laboratory, nine central laboratories, twenty-seven satellite centres, more than three hundred collection centres and located in Jaipur and across Uttar Pradesh and Uttarakhand, with facilities in more than 23 cities and towns across Uttar Pradesh and more than 19 cities and towns in Uttarakhand.

Services Offered: As of December 31, 2024, we provide a wide range of 1,496 tests across different specialties. Our test menu includes (a) 481 routine pathology tests, covering basic biochemistry and hematology, as well as 1,015 specialized pathology tests, such as immohistopathology, and molecular pathology, and (b) 545 radiology tests, including basic x-rays, ultrasonography (“USG”), computed tomography (“CT”), magnetic resonance imaging (“MRI”), and specialized CT scans.

Geographies Served: We presently have presence in Uttar Pradesh, Uttarakhand and Rajasthan.

Key Performance Indicators:

KEY PERFORMANCE INDICATORS

The key financial and operational performance indicators of our Company for the nine-month period ended December 31, 2024 and Fiscals 2024, 2023 and 2022 have been provided below:

(₹ in lakhs)

Particulars	For the period ended December 31, 2024	As of March 31, 2024	As of March 31, 2023	As of March 31, 2022
Revenue from operations	16,747.47	17,659.01	13,688.94	11,956.35
Growth (%)	-	29.00%	14.49%	-
Total income	16,798.82	17,795.86	13,702.92	11,991.58
Growth (%)	-	29.87%	14.27%	-
Earnings before interest, taxes, depreciation, and amortization (EBITDA)	3,009.12	2,610.28	927.41	215.75
EBITDA Margin (%)	17.97%	14.78%	6.77%	1.80%
Profit Before Tax (PBT)	2,340.49	2,146.01	501.12	(106.02)
PBT Margin (%)	13.98%	12.15%	3.66%	(0.89)%
Profit after Tax (PAT)	1,741.99	1,635.51	358.63	(109.25)
PAT Margin (%)	10.40%	9.26%	2.62%	(0.91)%
Net Worth	5,430.99	4,116.07	2,736.87	2,400.07
EPS	8.07	8.14	1.68	(0.55)
Debt Equity Ratio	0.96	1.02	0.78	0.69

Industries Served: Healthcare and Cosmetic, B2C, Government, Automobile, Banking, Financial Services, and Insurance, Institution and College, Information Technology, Travel Tourism, Food and Beverages, Power, Real Estate, Petrochemical, Retail, Cement, Entertainment, Media, Advertising and Events, Hotel, Telecom, Agro-Chemicals, Sugar.

Intellectual Property: As of the filing date of the Red Herring Prospectus, our Company holds 1 registered trademark.

Market Share: Not Ascertainable.

Employee Strength: As of December 31, 2024, we have 1,142 employees. For details see “Our Business –Employees” on page 180 of the RHP.

BOARD OF DIRECTORS

Sr. No.	Name and Designation	Experience & Educational Qualification	Directorships in other Companies
1.	Amar Singh <i>Chairman and Managing Director</i>	Educational Qualification: He holds a degree of Bachelor of Medicine and Bachelor of Surgery. Experience: He has over two decades of experience in the healthcare industry.	Indian Companies: <ul style="list-style-type: none"> Chandan Institute of Medical Sciences Limited Chandan Cancer Institute Limited Healthrely Private Limited Chandan Super Speciality Hospital Limited Chandan Diagnostic Limited Amaranita Holdings (India) Private Limited Chandan Pharmacy Limited Cendana Pharmaceuticals Private Limited Chandan Hospital Limited Foreign Companies: Nil
2.	Asmita Singh <i>Managing Director</i>	Educational Qualification: She holds a Bachelor of Business Administration and Master of Business. Experience: She has over two decades of experience in the field of marketing.	Indian Companies: <ul style="list-style-type: none"> Chandan Cancer Institute Limited Healthrely Private Limited Chandan Super Speciality Hospital Limited Chandan Institute of Medical Sciences Limited Chandan Hospital Limited Chandan Diagnostic Limited Indra Diagnostic Centre and Blood Bank Limited Kunwars Wellness Foundation Amaranita Holdings (India) Private Limited Chandan Pharmacy Limited Cendana Pharmaceuticals Private Limited Foreign Companies: Nil
3.	Vinay Lamba Non-Executive Director	Educational Qualification: He has completed his training from the Marine Engineering and Research Institute, Calcutta and has a certificate of competency as Marine Engineer Officer Class I of a Motorship. Experience: He has over one decade of experience in the field of technical operations. He was previously associated with Indra Diagnostic Centre and Blood Bank Limited as Operations head from 1999 to 2003.	Indian Companies: <ul style="list-style-type: none"> Chandan Cancer Institute Limited Chandan Super Speciality Hospital Limited Chandan Hospital Limited Chandan Pharmacy Limited Lambros Engineering and Technical Services Private Limited Chandan Diagnostic Limited Foreign Companies: Nil

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Sr. No.	Name and Designation	Experience & Educational Qualification	Directorships in other Companies
4.	Amit Gupta Independent Director	Educational Qualification: He holds Bachelor of Science degree and is a fellow member of Institute of Company Secretaries of India and holds a Diploma in Business finance from Institute of Chartered Financial Analysts of India and he holds Certificate of Practice. Experience: He has over two decades of experience in compliance and secretarial matters.	Indian Companies: • Rajasthan Liquors Limited Foreign Companies: Nil
5.	Brahma Nand Bhartiya Independent Director	Educational Qualification: He holds Bachelor of Arts and Master of Arts degree. Experience: He was previously associated with Department of Labour Commissioner, Uttar Pradesh, GT Road, Kanpur, as assistant labour commissioner retired in 2014.	Nil
6	Vinod Jain Independent Director	Educational Qualification: He holds Master of Surgery (General Surgery) he is a fellow in Art and Science of Surgery from American College of Surgeons and a fellow in General Surgery from International College of Surgeons. Experience: He was previously associated as Professor with King George Medical University, U.P., Lucknow from February 27, 1998 and superannuated in October 05, 2022.	Nil

For further details in relation to our Board of Directors, see "Our Management" beginning on page 200 of the RHP.

OBJECTS OF THE OFFER

The Offer comprises the Fresh Issue and Offer for sale.

The Offer for Sale

The Promoter Selling Shareholder, Promoter Group Selling Shareholders and Investor Selling Shareholders will be entitled to their respective portion of the proceeds of the Offer for Sale after deducting their respective proportion of Offer related expenses and relevant taxes thereon. Our Company will not receive any proceeds from the Offer for Sale and the proceeds received from the Offer for Sale will not form part of the Net Proceeds. Further, none of the objects for which the Net Proceeds will be utilised have been appraised by any agency or financial institution. For further details, please see "Offer Structure" on page 380 of the RHP.

Fresh Issue

Our Company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:

1. Setting up of a new Flagship Diagnostic Centre in Jankipuram, Lucknow, Uttar Pradesh.
2. Setting up of a new Central Reference laboratory at Ayodhya, Uttar Pradesh
3. Setting up of a new Central Reference laboratory at Ashiyana, Lucknow, Uttar Pradesh.
4. General corporate purposes

Net Proceeds

The details of the proceeds of the Offer are set forth in the table below:

(₹ in lakhs)

Particulars	Amount
Gross Proceeds of the Offer	●
Less: Offer for Sale	●
Less: Offer Expenses*	●
Net Proceeds**	●

*For details see "Offer Related Expenses" below on page 142.

** To be finalised upon determination of the Offer Price and updated in the Prospectus prior to the filing with the RoC.

Utilization of Net Proceeds

The Net Proceeds are proposed to be utilized and are currently expected to be deployed in accordance with the schedule set forth below:

We propose to utilize the Net Proceeds in the following manner:

(₹ in lakhs)

Sr No	Particulars	Estimated Amount
1	Setting up of a new Flagship diagnostic centre in Jankipuram, Lucknow, Uttar Pradesh.	3,281.58
2	Setting up of a new Central Reference laboratory at Ayodhya, Uttar Pradesh.	710.23
3	Setting up of a new Central Reference laboratory at Ashiyana, Lucknow, Uttar Pradesh.	710.11
4	General corporate purposes ⁽¹⁾	●
	Net Proceeds	●

⁽¹⁾ To be finalised upon determination of the Offer Price and updated in the Prospectus prior to filing with the RoC. The amount utilized for general corporate purposes shall not exceed 25% of the Gross Proceeds.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilisation of issue proceeds of past public offers / rights issues, if any, of our Company in the preceding 10 years: Nil.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Terms of Issuance of Convertible Security, if any: Not Applicable.

Name of Monitoring Agency: Not Applicable.

Shareholding Pattern as on the date of the RHP:

Category of Shareholder	Pre-Offer number of shares	% Holding of Pre-Offer
Promoter and Promoter Group	1,39,85,820	69.93%
Public	60,14,180	30.07%
Total	2,00,00,000	100.00

SUMMARY OF RESTATED FINANCIAL STATEMENTS

(Amount ₹ in Lakhs)

Sr. No.	Particulars	December 31, 2024	March 31, 2024	March 31, 2023	March 31, 2022
1	Share Capital	2,000.00	2,000.00	2,000.00	2,000.00
2	Net Worth	5,430.99	4,116.07	2,736.87	2,400.07
3	Revenue from operations	16,747.47	17,659.01	13,688.94	11,956.35
4	Profit after Tax	1,741.99	1,635.51	358.63	(109.25)
5	Earnings per Share	8.07	8.14	1.68	(0.55)
6	Net Asset Value per equity share	27.15	20.55	13.65	11.97
	Total borrowings	5,192.32	4,201.27	2,135.50	1,658.17

EXTERNAL RISK FACTORS

Below mentioned risks are the top 5 risk factors as per the RHP:

- 1) Any interruptions at our flagship diagnostic centres may affect our ability to process diagnostic tests, which in turn may adversely affect our business, results of operations and financial condition.
- 2) Our business and prospects may be adversely affected if we are unable to maintain and grow our brand name and brand image.
- 3) We are dependent on B2C and few other customers for a major part of our revenues. Further we do not enter long-term arrangements with our customers and any failure to continue our existing arrangements could adversely affect our business and results of operations.
- 4) Any non-renewal or cancellation of our arrangements with our institutional customers, including hospitals, and government agencies may adversely affect our business, results of operations and financial condition.
- 5) Our operations are only focused on Uttar Pradesh and Uttarakhand, and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.

Due to character limits prescribed in the applicable regulations, entire text of the Risk Factors has not been incorporated here. Please refer the section titled 'Risk Factors' on page 42 of the RHP for further details.

SUMMARY OF OUTSTANDING LITIGATIONS CLAIMS AND REGULATORY ACTION

A. A summary of outstanding litigation proceedings as on the date of the Red Herring Prospectus as disclosed in the section titled "Outstanding Litigations and Material Developments" in terms of the SEBI ICDR Regulations and the Materiality Policy is provided below:

Sr. No.	Outstanding Litigations	No. of Outstanding Matters	Financial implications to the extent quantifiable (₹ in Lakhs)
1	Cases against our Company		
	Criminal proceedings	Nil	Nil
	Material civil litigation	08	66.85
	Action by regulatory/statutory authorities	Nil	Nil
	Tax proceedings	01	194.67
	Other Matters	Nil	Nil
	Total	10	261.52
2	Cases by our Company		
	Criminal Proceedings	04	10.45
	Material Civil Proceedings	01	Nil
	Tax proceedings	Nil	Nil
	Other Matters	Nil	Nil
	Total	04	10.45
3	Cases against our Promoters		
	Criminal proceedings	Nil	Nil
	Material civil litigation	Nil	Nil
	Action by regulatory/statutory authorities	Nil	Nil
	Tax proceedings	Nil	Nil
	Other Matters	Nil	Nil
	Total	Nil	Nil
4	Cases by our Promoters		
	Material Civil Proceedings	Nil	Nil
	Criminal Proceedings	Nil	Nil

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Sr. No.	Outstanding Litigations	No. of Outstanding Matters	Financial implications to the extent quantifiable (₹ in Lakhs)
	Total	Nil	Nil
5	Cases against our Directors		
	Criminal proceedings	Nil	Nil
	Action by regulatory/statutory authorities	Nil	Nil
	Tax proceedings	Nil	Nil
	Material civil litigation	Nil	Nil
	Other Matters	Nil	Nil
	Total	Nil	Nil
6	Cases by our Directors		
	Material Civil Proceedings	Nil	Nil
	Criminal Proceedings	Nil	Nil
	Tax proceedings	Nil	Nil
	Other Matters	Nil	Nil
7	Cases against our Group Companies		
	Criminal proceedings	Nil	Nil
	Action by regulatory/statutory authorities	Nil	Nil
	Tax proceedings	Nil	Nil
	Material civil litigation	Nil	Nil
	Other Matters	Nil	Nil
	Total	Nil	Nil
8	Cases by our Group Companies		
	Criminal proceedings	04	6.88
	Action by regulatory/statutory authorities	Nil	Nil
	Tax proceedings	Nil	Nil
	Material civil litigation	Nil	Nil
	Other Matters	Nil	Nil
	Total	04	6.88
9	Cases against our Subsidiary Companies		
	Criminal proceedings	Nil	Nil
	Action by regulatory/statutory authorities	Nil	Nil
	Tax proceedings	Nil	Nil
	Material civil litigation	Nil	Nil
	Other Matters	Nil	Nil
	Total	Nil	Nil
10	Cases by our Subsidiary Companies		
	Criminal proceedings	02	12.70
	Action by regulatory/statutory authorities	Nil	Nil
	Tax proceedings	Nil	Nil
	Material civil litigation	Nil	Nil
	Other Matters	Nil	Nil
	Total	02	12.70
11	Cases by our Group Companies		
	Material Civil Proceedings	Nil	Nil
	Criminal Proceedings	06	19.60
	Total	06	19.60

For further details, please refer to the chapter titled “*Outstanding Litigations and Material Developments*” beginning on Page 305 of the Red Herring Prospectus.

B. Brief details of top 5 material outstanding litigations against the Company and amount involved:

Sr. No.	Particulars	Litigation filed by	Current Status	Amount involved
1	A complaint bearing no. 130/2020 dated April 13, 2020 (“ Compliant ”) has been filed by Manoj Kumar Gupta (“ Complainant ”) before the District Consumer Dispute Redressal Forum (“ DCDRF ”), Prayagraj against our Company, Indira Diagnostic Centre, Allahabad, Dr. Rakhi Tewari, and Dr. Vijay Soren (collectively the “ Respondents ”). In the Complaint, the Complainant alleged that, inter alia, one of the Respondents i.e., the Diagnostic Centre generated a deceptive blood examination report dated February 11, 2020, basis which medications were prescribed by the doctor to the Complainant. Later, the Complainant went for another blood examination and upon receiving the report of the second examination, the treatment of the Complainant was altered. The Complainant in the Complaint stated that due to the deceptive report, the Complainant suffered from various diseases which also had an adverse effect on his physical and mental health.	Manoj Kumar Gupta	This matter is pending	₹ 20 Lakhs

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Sr. No.	Particulars	Litigation filed by	Current Status	Amount involved
2	A complaint bearing no. 193/2010 dated July 26, 2010 (“ Compliant ”) has been filed by Vikas Agarwal (“ Complainant ”) before District Consumer Dispute Redressal Forum (“ DCDRF ”), Prayagraj, Lakhimpur against Dr. Manu Gopaland Chandan Diagnostic Centre, Lakhimpur (collectively the “ Respondents ”), alleging, <i>inter alia</i> , the deceptive ultra-sound examination report generated by one of the Respondent i.e., Chandan Diagnostic Centre, Lakhimpur. Based on the ultra-sound report shared by the said diagnostic centre, the Complainant approached Shekhar Hospital for further treatment. The Complainant also sought for another opinion where the results of a similar examination were contradictory to the reports of our diagnostic centre. Therefore, the Complainant filed the present Complaint claiming an amount of ₹ 16,20,000/- due to several financial, physical and mental loss suffered by the Complainant.	Vikas Agarwal	This matter is currently pending.	₹ 16.20 lakhs
3	A complaint bearing no. 203/2015 dated March 22, 2016 (“ Compliant ”) has been filed by Israfil (“ Complainant ”) before District Consumer Dispute Redressal Forum (“ DCDRF ”), Lakhimpur Khiri against Chandan Diagnostic Centre, Lakhimpur and Dr. Harishanker (collectively the “ Respondents ”) alleging, <i>inter alia</i> , medical negligence against the Respondents. The matter relates to the Complainant’s wife (“ Patient ”) who had an acute pain in her chest and was diagnosed with gallstone basis the report issued by one of the Respondent i.e., Chandan Diagnostic Centre, Lakhimpur. The Patient was referred to Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow as she suffered from post-operative consequences. It was also alleged that the Patient underwent a major operation because of gross negligence of the Respondents. Hence, the Complainant filed the present Complaint claiming an amount of ₹ 10,00,000/- due to several financial, physical and mental loss suffered by him and the Patient.	Israfil	This matter is currently pending.	₹ 10.00 lakhs
4	An application bearing no. 96/2020 dated July 21, 2020 (“ Applicant ”) has been filed by Amit Singh (“ Application ”) before Presiding Officer, Labor Court, 23 A.P. Sen Road, Lucknow, against Director Chandan HealthCare Limited, Dilshad Garden, East Delhi and Director Chandan HealthCare Limited, Biotech park, Lucknow (collectively the “ Respondents ”), alleging, <i>inter alia</i> , for illegal termination of employment and non-payment of retrenchment and other benefits. The Applicant was employed from August 1, 2017 to March 24, 2020 as per the attendance register but was not paid any compensation in respect to his employment and later was terminated, therefore he claims compensation for an amount of ₹ 5,45,400/-.	Amit Singh	This matter is currently pending.	₹ 5.45 Lakhs
5	A Complaint bearing no. 1000/2011 dated April 1, 2011 (“ Compliant ”) has been filed by Yogendra Kumar Singh (“ Complainant ”) before District Consumer Dispute Redressal Forum (“ DCDRF ”), Lucknow, against Indira Diagnostic Centre, Allahabad and Director Chandan HealthCare Limited (collectively the “ Respondents ”), alleging, <i>inter alia</i> , the deceptive ECG examination report generated by one of the Respondent i.e., Indira Diagnostic Centre, Allahabad. Based on the ECG report shared by Respondent, the Complainant was suffering from a heart disease. The Complainant also sought another opinion where the results of the similar examination were contradictory to the reports of our diagnostic centre which further altered the Complainant's treatment. The Complainant stated that due to the deceptive report, the Complainant suffered from various diseases which also had an adverse effect on his physical and mental health. Therefore, the Complainant filed the present Complaint claiming compensation for an amount of ₹ 5,00,000/-for medical negligence.	Yogendra Kumar Singh	This matter is currently pending.	₹ 5.00 Lakhs

C. **Regulatory Action, if any - disciplinary action taken by SEBI or stock exchanges against the Promoter in the last 5 financial years including outstanding action, if any:** Nil

D. **Brief details of outstanding criminal proceedings against the Promoter:** Nil

For further details of the outstanding litigation proceedings, see “*Outstanding Litigation and Material Developments*” on page 305 of the RHP.

ANY OTHER INFORMATION AS PER BOOK RUNNING LEAD MANAGER/ COMPANY: NIL
DECLARATION BY OUR COMPANY

We hereby declare that all relevant provisions of the Companies Act and the rules, guidelines/ regulations issued by the Government of India or the guidelines/ regulations issued by the Securities and Exchange Board of India, established under Section 3 of the SEBI Act, 1992, as the case may be, have been complied with and no statement made in the Red Herring Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act or the rules made or guidelines or regulation issued there under, as the case may be. We further certify that all statements in the Red Herring Prospectus are true and correct.